Liquidia (NASDAQ:LQDA) CFO Sells 23,821 Shares

Key Points

• Liquidia CFO Michael Kaseta sold 23,821 shares on April 10 at an average price of $40.14 for about $956,175, reducing his stake to 411,855 shares (a 5.47% decrease); the sale was executed under a pre-arranged Rule 10b5-1 plan to cover tax withholding on vested equity.
• Those shares were part of broader insider selling in early April — Kaseta also sold 133,789 shares on April 9 for roughly $5.38 million and 18,958 shares on April 13 for about $727,418.
• Stock and analyst snapshot: LQDA traded near $38.71 (52-week range $11.85–$46.67) with a $3.41B market cap; the company recently beat quarterly EPS estimates and showed massive YoY revenue growth, and analysts hold a consensus "Moderate Buy" with a $43.44 target.

Liquidia Corporation (NASDAQ:LQDA - Get Free Report) CFO Michael Kaseta sold 23,821 shares of the company's stock in a transaction that occurred on Friday, April 10th. The shares were sold at an average price of $40.14, for a total value of $956,174.94. Following the completion of the transaction, the chief financial officer owned 411,855 shares in the company, valued at approximately $16,531,859.70. The trade was a 5.47% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Michael Kaseta also recently made the following trade(s):

• On Monday, April 13th, Michael Kaseta sold 18,958 shares of Liquidia stock. The stock was sold at an average price of $38.37, for a total value of $727,418.46.
• On Thursday, April 9th, Michael Kaseta sold 133,789 shares of Liquidia stock. The shares were sold at an average price of $40.24, for a total value of $5,383,669.36.

Liquidia Stock Performance

Shares of LQDA traded down $0.14 during mid-day trading on Tuesday, hitting $38.71. The stock had a trading volume of 844,813 shares, compared to its average volume of 1,775,539. Liquidia Corporation has a 52 week low of $11.85 and a 52 week high of $46.67. The company has a debt-to-equity ratio of 2.97, a current ratio of 2.01 and a quick ratio of 1.84. The business has a fifty day moving average price of $36.87 and a 200-day moving average price of $32.92. The firm has a market cap of $3.41 billion, a P/E ratio of -46.64 and a beta of 0.45.

Liquidia (NASDAQ:LQDA - Get Free Report) last posted its quarterly earnings results on Thursday, March 5th. The company reported $0.15 earnings per share for the quarter, topping the consensus estimate of $0.08 by $0.07. Liquidia had a negative return on equity of 209.33% and a negative net margin of 43.53%.The company had revenue of $92.02 million during the quarter, compared to the consensus estimate of $87.49 million. The business's revenue was up 3072.4% compared to the same quarter last year. On average, equities research analysts expect that Liquidia Corporation will post -1.51 EPS for the current year.

Institutional Investors Weigh In On Liquidia

Several hedge funds have recently bought and sold shares of LQDA. Seven Fleet Capital Management LP purchased a new position in Liquidia in the 4th quarter worth approximately $3,148,000. Invesco Ltd. raised its position in shares of Liquidia by 428.3% during the 4th quarter. Invesco Ltd. now owns 420,621 shares of the company's stock valued at $14,507,000 after buying an additional 341,009 shares in the last quarter. XTX Topco Ltd bought a new stake in shares of Liquidia during the 4th quarter worth $1,214,000. nVerses Capital LLC bought a new stake in shares of Liquidia during the 4th quarter worth $335,000. Finally, Occudo Quantitative Strategies LP purchased a new position in Liquidia in the fourth quarter worth $3,107,000. 64.54% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on LQDA shares. HC Wainwright lifted their target price on shares of Liquidia from $50.00 to $55.00 and gave the stock a "buy" rating in a research note on Friday, March 6th. Wells Fargo & Company upped their price target on shares of Liquidia from $44.00 to $51.00 and gave the company an "overweight" rating in a research note on Monday, March 23rd. Wall Street Zen upgraded shares of Liquidia from a "hold" rating to a "buy" rating in a research note on Saturday, March 7th. Raymond James Financial reissued a "strong-buy" rating on shares of Liquidia in a report on Thursday, March 5th. Finally, Zacks Research downgraded Liquidia from a "strong-buy" rating to a "hold" rating in a research report on Friday, February 27th. Two analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $43.44.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company's lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.